Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Udaya B. Kompella

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-4028

    Collapse Overview 

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022 03 10; 65(5):3943-3961. PMID: 35192363.
      View in: PubMed
    2. Chalimeswamy A, Thanuja MY, Ranganath SH, Pandya K, Kompella UB, Srinivas SP. Oxidative Stress Induces a Breakdown of the Cytoskeleton and Tight Junctions of the Corneal Endothelial Cells. J Ocul Pharmacol Ther. 2022 Jan-Feb; 38(1):74-84. PMID: 34818079.
      View in: PubMed
    3. Chhunchha B, Kubo E, Kompella UB, Singh DP. Engineered Sumoylation-Deficient Prdx6 Mutant Protein-Loaded Nanoparticles Provide Increased Cellular Defense and Prevent Lens Opacity. Antioxidants (Basel). 2021 Aug 04; 10(8). PMID: 34439493.
      View in: PubMed
    4. Patil MA, Kompella UB. Noninvasive monitoring of suprachoroidal, subretinal, and intravitreal implants using confocal scanning laser ophthalmoscope (cSLO) and optical coherence tomography (OCT). Int J Pharm. 2021 Sep 05; 606:120887. PMID: 34271155.
      View in: PubMed
    5. Liu Z, Kompella UB, Chauhan A. Gold nanoparticle synthesis in contact lenses for drug-less ocular cystinosis treatment. Eur J Pharm Biopharm. 2021 Aug; 165:271-278. PMID: 34044109.
      View in: PubMed
    6. Dube T, Ghosh A, Mishra J, Kompella UB, Panda JJ. Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. Adv Ther (Weinh). 2021 Feb; 4(2):2000172. PMID: 33173808.
      View in: PubMed
    7. Kompella UB, Hartman RR, Patil MA. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Prog Retin Eye Res. 2021 05; 82:100901. PMID: 32891866.
      View in: PubMed
    8. Raol YH, Joksimovic SM, Sampath D, Matter BA, Lam PM, Kompella UB, Todorovic SM, González MI. The role of KCC2 in hyperexcitability of the neonatal brain. Neurosci Lett. 2020 11 01; 738:135324. PMID: 32860887.
      View in: PubMed
    9. Vooturi S, Bourne D, Panda JJ, Choi S, Kim H, Yandrapu SK, Kompella UB. Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid. J Ocul Pharmacol Ther. 2020 Jul/Aug; 36(6):404-409. PMID: 32678687.
      View in: PubMed
    10. Patil MA, Kompella UB. Noninvasive Monitoring of Choroid-Retina Autofluorescence and Intravitreal Nanoparticle Disposition in Royal College of Surgeon Rats of Different Ages and Retinal Thinning. J Ocul Pharmacol Ther. 2020 Jul/Aug; 36(6):458-466. PMID: 32552217.
      View in: PubMed
    11. Kelley RA, Ghaffari A, Wang Y, Choi S, Taylor JR, Hartman RR, Kompella UB. Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons. J Ocul Pharmacol Ther. 2020 06; 36(5):290-297. PMID: 32330403.
      View in: PubMed
    12. Damiati S, Scheberl A, Zayni S, Damiati SA, Schuster B, Kompella UB. Albumin-bound nanodiscs as delivery vehicle candidates: Development and characterization. Biophys Chem. 2019 08; 251:106178. PMID: 31102749.
      View in: PubMed
    13. Sudhir RR, Murthy PP, Tadepalli S, Murugan S, Padmanabhan P, Krishnamurthy A, Dickinson SL, Karthikeyan R, Kompella UB, Srinivas SP. Ocular Spot Fluorometer Equipped With a Lock-In Amplifier for Measurement of Aqueous Flare. Transl Vis Sci Technol. 2018 Nov; 7(6):32. PMID: 30619652.
      View in: PubMed
    14. Patil MA, Matter BA, Raol YH, Bourne DWA, Kelley RA, Kompella UB. Brain Distribution and Metabolism of Flupirtine, a Nonopioid Analgesic Drug with Antiseizure Effects, in Neonatal Rats. Pharmaceutics. 2018 Dec 16; 10(4). PMID: 30558371.
      View in: PubMed
    15. Patil MA, Upadhyay AK, Hernandez-Lagunas L, Good R, Carpenter TC, Sucharov CC, Nozik-Grayck E, Kompella UB. Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature. Artif Cells Nanomed Biotechnol. 2018; 46(sup3):S1059-S1066. PMID: 30450979.
      View in: PubMed
    16. Lenin R, Nagy PG, Alli S, Rao VR, Clauss MA, Kompella UB, Gangaraju R. Critical role of endoplasmic reticulum stress in chronic endothelial activation-induced visual deficits in tie2-tumor necrosis factor mice. J Cell Biochem. 2018 11; 119(10):8460-8471. PMID: 30054947.
      View in: PubMed
    17. Good RJ, Hernandez-Lagunas L, Allawzi A, Maltzahn JK, Vohwinkel CU, Upadhyay AK, Kompella UB, Birukov KG, Carpenter TC, Sucharov CC, Nozik-Grayck E. MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability. Am J Physiol Lung Cell Mol Physiol. 2018 10 01; 315(4):L584-L594. PMID: 30024304.
      View in: PubMed
    18. Srinivas SP, Goyal A, Talele DP, Mahadik S, Sudhir RR, Murthy PP, Ranganath S, Kompella UB, Padmanabhan P. Corneal epithelial permeability to fluorescein in humans by a multi-drop method. PLoS One. 2018; 13(6):e0198831. PMID: 29920519.
      View in: PubMed
    19. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 31259643.
      View in: PubMed
    20. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 31646399.
      View in: PubMed
    21. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 32901367.
      View in: PubMed
    22. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35189576.
      View in: PubMed
    23. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35819539.
      View in: PubMed
    24. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 1934087.
      View in: PubMed
    25. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 12167462.
      View in: PubMed
    26. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 9090616.
      View in: PubMed
    27. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 7511088.
      View in: PubMed
    28. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18812595.
      View in: PubMed
    29. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21945644.
      View in: PubMed
    30. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 12480311.
      View in: PubMed
    31. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 10504031.
      View in: PubMed
    32. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22467572.
      View in: PubMed
    33. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16180166.
      View in: PubMed
    34. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18841448.
      View in: PubMed
    35. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19194480.
      View in: PubMed
    36. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21738619.
      View in: PubMed
    37. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23485089.
      View in: PubMed
    38. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 10344624.
      View in: PubMed
    39. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 15451004.
      View in: PubMed
    40. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 15792788.
      View in: PubMed
    41. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18032574.
      View in: PubMed
    42. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21346004.
      View in: PubMed
    43. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19920099.
      View in: PubMed
    44. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22841772.
      View in: PubMed
    45. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18275910.
      View in: PubMed
    46. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23272048.
      View in: PubMed
    47. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 12916933.
      View in: PubMed
    48. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18987961.
      View in: PubMed
    49. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17563725.
      View in: PubMed
    50. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 7901046.
      View in: PubMed
    51. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 10211712.
      View in: PubMed
    52. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21574814.
      View in: PubMed
    53. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11465409.
      View in: PubMed
    54. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16505053.
      View in: PubMed
    55. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 15553225.
      View in: PubMed
    56. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23532520.
      View in: PubMed
    57. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 19667343.
      View in: PubMed
    58. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 15965845.
      View in: PubMed
    59. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 21402977.
      View in: PubMed
    60. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 11259842.
      View in: PubMed
    61. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 18172109.
      View in: PubMed
    62. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 20025945.
      View in: PubMed
    63. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23734705.
      View in: PubMed
    64. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23940587.
      View in: PubMed
    65. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 24856785.
      View in: PubMed
    66. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 25275914.
      View in: PubMed
    67. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22888471.
      View in: PubMed
    68. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 26299959.
      View in: PubMed
    69. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 27783270.
      View in: PubMed
    70. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28738417.
      View in: PubMed
    71. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29206556.
      View in: PubMed
    72. Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29152562.
      View in: PubMed
    73. Damiati S, Kompella UB, Damiati SA, Kodzius R. Microfluidic Devices for Drug Delivery Systems and Drug Screening. Genes (Basel). 2018 Feb 16; 9(2). PMID: 29462948.
      View in: PubMed
    74. Muralidharan R, Babu A, Amreddy N, Srivastava A, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486. PMID: 28572169.
      View in: PubMed
    75. Zhang X, Bohner A, Bhuvanagiri S, Uehara H, Upadhyay AK, Emerson LL, Bondalapati S, Muddana SK, Fang D, Li M, Sandhu Z, Hussain A, Carroll LS, Tiem M, Archer B, Kompella U, Patil R, Ambati BK. Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment. Mol Ther. 2017 07 05; 25(7):1606-1615. PMID: 28236576.
      View in: PubMed
    76. Chaiyasan W, Praputbut S, Kompella UB, Srinivas SP, Tiyaboonchai W. Penetration of mucoadhesive chitosan-dextran sulfate nanoparticles into the porcine cornea. Colloids Surf B Biointerfaces. 2017 Jan 01; 149:288-296. PMID: 27771493.
      View in: PubMed
    77. Muralidharan R, Babu A, Amreddy N, Basalingappa K, Mehta M, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 2016 Jun 21; 14(1):47. PMID: 27328938.
      View in: PubMed
    78. Wang Z, Cheng R, Lee K, Tyagi P, Ding L, Kompella UB, Chen J, Xu X, Ma JX. Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization. Arterioscler Thromb Vasc Biol. 2015 Apr; 35(4):855-64. PMID: 25657312.
      View in: PubMed
    79. Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL, Grossniklaus HE, Naash MI, Lewin AS, Horsager A, Edelhauser HF. Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci. 2014 Apr 28; 55(4):2714-30. PMID: 24777644.
      View in: PubMed
    80. Rajashekhar G, Shivanna M, Kompella UB, Wang Y, Srinivas SP. Role of MMP-9 in the breakdown of barrier integrity of the corneal endothelium in response to TNF-a. Exp Eye Res. 2014 May; 122:77-85. PMID: 24667088.
      View in: PubMed
    81. Kim SJ, Toma H, Shah R, Kompella UB, Vooturi SK, Sheng J. The safety, pharmacokinetics, and efficacy of intraocular celecoxib. Invest Ophthalmol Vis Sci. 2014 Mar 10; 55(3):1409-18. PMID: 24458149.
      View in: PubMed
    82. Cruz NM, Yuan Y, Leehy BD, Baid R, Kompella U, DeAngelis MM, Escher P, Haider NB. Modifier genes as therapeutics: the nuclear hormone receptor Rev Erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease. PLoS One. 2014; 9(1):e87942. PMID: 24498227.
      View in: PubMed
    83. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm. 2013 Dec 02; 10(12):4676-86. PMID: 24131101.
      View in: PubMed
    84. Rao VR, Upadhyay AK, Kompella UB. pH shift assembly of adenoviral serotype 5 capsid protein nanosystems for enhanced delivery of nanoparticles, proteins and nucleic acids. J Control Release. 2013 Nov 28; 172(1):341-350. PMID: 24004886.
      View in: PubMed
    85. Tari SR, Youssif M, Samson CM, Harris RL, Lin CM, Kompella UB, Antonetti DA, Barile GR. Polychromatic angiography for the assessment of VEGF-induced BRB dysfunction in the rabbit retina. Invest Ophthalmol Vis Sci. 2013 Aug 15; 54(8):5550-8. PMID: 23882687.
      View in: PubMed
    86. Bargagna-Mohan P, Deokule SP, Thompson K, Wizeman J, Srinivasan C, Vooturi S, Kompella UB, Mohan R. Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis. PLoS One. 2013; 8(5):e63881. PMID: 23667686.
      View in: PubMed
    87. Baid R, Upadhyay AK, Shinohara T, Kompella UB. Biosynthesis, characterization, and efficacy in retinal degenerative diseases of lens epithelium-derived growth factor fragment (LEDGF1-326), a novel therapeutic protein. J Biol Chem. 2013 Jun 14; 288(24):17372-83. PMID: 23640891.
      View in: PubMed
    88. Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013 Sep; 36:172-98. PMID: 23603534.
      View in: PubMed
    89. Dhanda DS, Tyagi P, Mirvish SS, Kompella UB. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J Control Release. 2013 Jun 28; 168(3):239-50. PMID: 23562638.
      View in: PubMed
    90. Luo L, Zhang X, Hirano Y, Tyagi P, Barabás P, Uehara H, Miya TR, Singh N, Archer B, Qazi Y, Jackman K, Das SK, Olsen T, Chennamaneni SR, Stagg BC, Ahmed F, Emerson L, Zygmunt K, Whitaker R, Mamalis C, Huang W, Gao G, Srinivas SP, Krizaj D, Baffi J, Ambati J, Kompella UB, Ambati BK. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano. 2013 Apr 23; 7(4):3264-75. PMID: 23464925.
      View in: PubMed
    91. Kadam R, Bourne D, Kompella U, Aquilante C. Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers. Biol Pharm Bull. 2013; 36(2):245-51. PMID: 23370354.
      View in: PubMed
    92. Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013 Jan; 75(1):217-26. PMID: 22625877.
      View in: PubMed
    93. Yandrapu S, Kompella UB. Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. J Ocul Pharmacol Ther. 2013 Mar; 29(2):236-48. PMID: 23256487.
      View in: PubMed
    94. Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology. 2012 Dec 21; 23(50):505101. PMID: 23186914.
      View in: PubMed
    95. Tyagi P, Kadam RS, Kompella UB. Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS One. 2012; 7(10):e48188. PMID: 23118950.
      View in: PubMed
    96. Kadam RS, Scheinman RI, Kompella UB. Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier. Mol Pharm. 2012 Nov 05; 9(11):3228-35. PMID: 23003570.
      View in: PubMed
    97. Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano. 2012 Sep 25; 6(9):7595-606. PMID: 22876910.
      View in: PubMed
    98. Cho YK, Uehara H, Young JR, Tyagi P, Kompella UB, Zhang X, Luo L, Singh N, Archer B, Ambati BK. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci. 2012 Apr 30; 53(4):2328-36. PMID: 22427553.
      View in: PubMed
    99. Kadam RS, Bourne DW, Kompella UB. Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos. 2012 Jul; 40(7):1380-8. PMID: 22498894.
      View in: PubMed
    100. Durairaj C, Chastain JE, Kompella UB. Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res. 2012 May; 98:23-7. PMID: 22440812.
      View in: PubMed
    101. Durazo SA, Kompella UB. Functionalized nanosystems for targeted mitochondrial delivery. Mitochondrion. 2012 Mar; 12(2):190-201. PMID: 22138492.
      View in: PubMed
    102. Scheinman RI, Trivedi R, Vermillion S, Kompella UB. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond). 2011 Dec; 6(10):1669-82. PMID: 22087799.
      View in: PubMed
    103. Holden CA, Tyagi P, Thakur A, Kadam R, Jadhav G, Kompella UB, Yang H. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine. 2012 Jul; 8(5):776-83. PMID: 21930109.
      View in: PubMed
    104. Baid R, Scheinman RI, Shinohara T, Singh DP, Kompella UB. LEDGF(1-326) decreases P23H and wild type rhodopsin aggregates and P23H rhodopsin mediated cell damage in human retinal pigment epithelial cells. PLoS One. 2011; 6(9):e24616. PMID: 21915354.
      View in: PubMed
    105. Jin J, Zhou KK, Park K, Hu Y, Xu X, Zheng Z, Tyagi P, Kompella UB, Ma JX. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Invest Ophthalmol Vis Sci. 2011 Aug 05; 52(9):6230-7. PMID: 21357401.
      View in: PubMed
    106. Durazo SA, Kadam RS, Drechsel D, Patel M, Kompella UB. Brain mitochondrial drug delivery: influence of drug physicochemical properties. Pharm Res. 2011 Nov; 28(11):2833-47. PMID: 21796482.
      View in: PubMed
    107. Kadam RS, Jadhav G, Ogidigben M, Kompella UB. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Drug Metab Dispos. 2011 Sep; 39(9):1529-37. PMID: 21673129.
      View in: PubMed
    108. Pfeifer T, Buchebner M, Chandak PG, Patankar J, Kratzer A, Obrowsky S, Rechberger GN, Kadam RS, Kompella UB, Kostner GM, Kratky D, Levak-Frank S. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol. 2011 Feb 01; 12(2):285-92. PMID: 21190543.
      View in: PubMed
    109. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, Csaky KG, Olsen TW, Kompella UB, Holers VM, Hageman GS, Gilger BC, Campochiaro PA, Whitcup SM, Wong WT. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5403-20. PMID: 20980702.
      View in: PubMed
    110. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010 Sep; 1(3):435-56. PMID: 21399724.
      View in: PubMed
    111. Durairaj C, Kadam RS, Chandler JW, Hutcherson SL, Kompella UB. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5804-16. PMID: 20484584.
      View in: PubMed
    112. Rao VR, Prescott E, Shelke NB, Trivedi R, Thomas P, Struble C, Gadek T, O'Neill CA, Kompella UB. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct; 51(10):5198-204. PMID: 20445119.
      View in: PubMed
    113. Amrite A, Pugazhenthi V, Cheruvu N, Kompella U. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert Opin Drug Deliv. 2010 May; 7(5):631-45. PMID: 20205602.
      View in: PubMed
    114. Missel P, Chastain J, Mitra A, Kompella U, Kansara V, Duvvuri S, Amrite A, Cheruvu N. In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. J Ocul Pharmacol Ther. 2010 Apr; 26(2):137-46. PMID: 20415622.
      View in: PubMed
    115. Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond). 2010 Apr; 5(3):485-505. PMID: 20394539.
      View in: PubMed
    116. Sunkara G, Ayalasomayajula SP, DeRuiter J, Kompella UB. Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor. Brain Res Bull. 2010 Feb 15; 81(2-3):327-32. PMID: 19761819.
      View in: PubMed
    117. Barañano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol. 2009 Oct; 93(10):1387-90. PMID: 19628498.
      View in: PubMed
    118. Sundaram S, Roy SK, Ambati BK, Kompella UB. Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J. 2009 Nov; 23(11):3752-65. PMID: 19608628.
      View in: PubMed
    119. Durairaj C, Kim SJ, Edelhauser HF, Shah JC, Kompella UB. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci. 2009 Oct; 50(10):4887-97. PMID: 19516015.
      View in: PubMed
    120. Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther. 2009 Jun; 8(6):1655-65. PMID: 19509261.
      View in: PubMed
    121. Park K, Chen Y, Hu Y, Mayo AS, Kompella UB, Longeras R, Ma JX. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes. 2009 Aug; 58(8):1902-13. PMID: 19491211.
      View in: PubMed
    122. Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther. 2009 Apr; 25(2):97-103. PMID: 19284324.
      View in: PubMed
    123. Kim ES, Durairaj C, Kadam RS, Lee SJ, Mo Y, Geroski DH, Kompella UB, Edelhauser HF. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res. 2009 May; 26(5):1155-61. PMID: 19194787.
      View in: PubMed
    124. Kadam RS, Kompella UB. Cassette analysis of eight beta-blockers in bovine eye sclera, choroid-RPE, retina, and vitreous by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15; 877(3):253-60. PMID: 19117816.
      View in: PubMed
    125. Sundaram S, Roy SK, Kompella UB. Differential expression of LHRH-receptor in bovine nasal tissue and its role in deslorelin delivery. Peptides. 2009 Feb; 30(2):351-8. PMID: 18992782.
      View in: PubMed
    126. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008 Jan 29; 14:150-60. PMID: 18334929.
      View in: PubMed
    127. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1):333-41. PMID: 18172110.
      View in: PubMed
    128. Kompella UB. Drug delivery to the back of the eye. Arch Soc Esp Oftalmol. 2007 Nov; 82(11):667-8; 669-70. PMID: 17979032.
      View in: PubMed
    129. Raghava S, Kompella UB. AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders. Eur J Pharmacol. 2007 Jul 30; 568(1-3):68-74. PMID: 17543940.
      View in: PubMed
    130. Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, Amin S, Kompella UB, Ambati BK. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 2007 May; 48(5):2030-6. PMID: 17460257.
      View in: PubMed
    131. Kador PF, Randazzo J, Babb T, Koushik K, Takamura Y, Zhu W, Blessing K, Kompella UB. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther. 2007 Apr; 23(2):116-23. PMID: 17444799.
      View in: PubMed
    132. Marra M, Gukasyan HJ, Raghava S, Kompella UB. 2nd Ophthalmic Drug Development and Delivery Summit. Expert Opin Drug Deliv. 2007 Jan; 4(1):77-85. PMID: 17184164.
      View in: PubMed
    133. Kompella UB, Sundaram S, Raghava S, Escobar ER. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol Vis. 2006 Oct 17; 12:1185-98. PMID: 17102798.
      View in: PubMed
    134. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci. 2006 Oct; 47(10):4513-22. PMID: 17003447.
      View in: PubMed
    135. Margalit E, Kugler LJ, Brumm MV, Meza JL, Kompella UB, Escobar ER, Christensen GR. The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci. 2006 May; 47(5):2093-9. PMID: 16639020.
      View in: PubMed
    136. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005 Dec; 57(12):1555-63. PMID: 16354399.
      View in: PubMed
    137. Bandi N, Ayalasomayajula SP, Dhanda DS, Iwakawa J, Cheng PW, Kompella UB. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol. 2005 Jul; 57(7):851-60. PMID: 15969944.
      View in: PubMed
    138. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004 Nov; 1(1):99-114. PMID: 16296723.
      View in: PubMed
    139. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol. 2004 Sep 13; 498(1-3):275-8. PMID: 15364005.
      View in: PubMed
    140. Koushik KN, Kompella UB. Transport of deslorelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue. J Pharm Pharmacol. 2004 Jul; 56(7):861-8. PMID: 15233864.
      View in: PubMed
    141. Koushik K, Dhanda DS, Cheruvu NP, Kompella UB. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res. 2004 Jul; 21(7):1119-26. PMID: 15290850.
      View in: PubMed
    142. Koushik K, Bandi N, Sundaram S, Kompella UB. Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm Res. 2004 Jun; 21(6):1034-46. PMID: 15212170.
      View in: PubMed
    143. Koushik K, Kompella UB. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm Res. 2004 Mar; 21(3):524-35. PMID: 15070105.
      View in: PubMed
    144. Sunkara G, Ayalasomayajula SP, Rao CS, Vennerstrom JL, DeRuiter J, Kompella UB. Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. J Pharm Pharmacol. 2004 Mar; 56(3):351-8. PMID: 15025860.
      View in: PubMed
    145. Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol. 2003 Sep; 55(9):1199-206. PMID: 14604462.
      View in: PubMed
    146. Koushik K, Sunkara G, Gwilt P, Kompella UB. Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1). Pharm Res. 2003 May; 20(5):779-87. PMID: 12751634.
      View in: PubMed
    147. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003 Mar; 44(3):1192-201. PMID: 12601049.
      View in: PubMed
    148. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003 Jan 05; 458(3):283-9. PMID: 12504784.
      View in: PubMed
    149. Zhang L, Parsons DL, Navarre C, Kompella UB. Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release. 2002 Dec 13; 85(1-3):73-81. PMID: 12480313.
      View in: PubMed
    150. Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002 Mar; 19(3):278-85. PMID: 11934234.
      View in: PubMed
    151. Bandi N, Kompella UB. Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). Eur J Pharmacol. 2002 Feb 15; 437(1-2):9-17. PMID: 11864633.
      View in: PubMed
    152. Koushik KN, Bandi N, Kompella UB. Interaction of [D-Trp6, Des-Gly10] LHRH ethylamide and hydroxy propyl beta-cyclodextrin (HPbetaCD): thermodynamics of interaction and protection from degradation by alpha-chymotrypsin. Pharm Dev Technol. 2001 Nov; 6(4):595-606. PMID: 11775960.
      View in: PubMed
    153. Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol. 2001 Aug 10; 425(2):109-16. PMID: 11502275.
      View in: PubMed
    154. Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carrier Syst. 2001; 18(2):173-99. PMID: 11325031.
      View in: PubMed
    155. Sunkara G, Deruiter J, Clark CR, Kompella UB. In-vitro hydrolysis, permeability, and ocular uptake of prodrugs of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor. J Pharm Pharmacol. 2000 Sep; 52(9):1113-22. PMID: 11045892.
      View in: PubMed
    156. Ayalasomayajula SP, Kompella UB. Drug efflux pumps: challenges and opportunities. 14-18 November 1999, New Orleans, LA, USA. IDrugs. 2000 Feb; 3(2):148-9. PMID: 16107925.
      View in: PubMed
    157. Kompella UB. Drug delivery applications of supercritical fluid technology. IDrugs. 1999 Jan; 2(1):33-4. PMID: 16180167.
      View in: PubMed
    158. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 1998; 5(6):415-41. PMID: 9783675.
      View in: PubMed
    159. Dani BA, Kompella UB. Inhibition of corneal metabolism of deslorelin by EDTA and ZnCl2. Drug Dev Ind Pharm. 1998 Jan; 24(1):11-7. PMID: 15605592.
      View in: PubMed
    160. Hosoya K, Kompella UB, Kim KJ, Lee VH. Contribution of Na(+)-glucose cotransport to the short-circuit current in the pigmented rabbit conjunctiva. Curr Eye Res. 1996 Apr; 15(4):447-51. PMID: 8670745.
      View in: PubMed
    161. Kompella UB, Kim KJ, Shiue MH, Lee VH. Cyclic AMP modulation of active ion transport in the pigmented rabbit conjunctiva. J Ocul Pharmacol Ther. 1996; 12(3):281-7. PMID: 8875334.
      View in: PubMed
    162. Kompella UB, Dani BA. Metabolism of [Des-Gly10,D-Trp6]LHRH ethylamide in rabbit nasal tissue. Life Sci. 1996; 58(24):2201-7. PMID: 8649206.
      View in: PubMed
    163. Kompella UB, Kim KJ, Shiue MH, Lee VH. Possible existence of Na(+)-coupled amino acid transport in the pigmented rabbit conjunctiva. Life Sci. 1995; 57(15):1427-31. PMID: 7674833.
      View in: PubMed
    Kompella's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)